You are on page 1of 1

Colombia

Tuberculosis profile
Population 2010 (millions) Estimates of burden * 2010 Mortality (excluding HIV) Prevalence (incl HIV) Incidence (incl HIV) Incidence (HIV-positive) Case detection, all forms (%) Case notifications 2010 New cases Smear-positive Smear-negative Smear unknown Extrapulmonary Other Total new Total < 15 years Number (thousands) 1.3 22 16 1.1 72 (0.81.9) (9.137) (1319) (0.751.5) (6087) 46 Rate (per 100 000 pop) 2.8 (1.74.2) 48 (2081) 34 (2841) 2.4 (1.63.3) Incidence (HIV+TB in orange), notifications (black) (rates per 100 000 population) 80 60 40 20 0 1990 1992 1994 1996 1998 2000 2002 2004 2006 20082010 Prevalence (rate per 100 000 population) 7 028 1 319 377 1 985 311 11 020 719 (%) (64) (12) (3) (18) (3) Retreatment cases Relapse Treatment after failure Treatment after default Other Total retreatment 400 61 408 0 869 (%) (46) (7) (47) (0) 200 150 100 50 0 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 Mortality excluding HIV (rate per 100 000 population) 10 8 6 Yes 100 Yes 4 2 0 1990 1992 1994 1996 1998 2000 2002 2004 2006 20082010 TB/HIV 2010 TB patients with known HIV status 5 079 % of TB patients with known HIV status 43 TB patients that are HIV-positive 1 231 % of tested TB patients that are HIV-positive 24 % HIV-positive TB patients started on CPT % HIV-positive TB patients started on ART 35 HIV-positive people screened for TB HIV-positive people provided with IPT CPT (orange) and ART (green) for HIV-positive TB patients (blue) 1500 1000 MDR-TB, Estimates among notified cases * % of new TB cases with MDR-TB % of retreatment TB cases with MDR-TB Estimated MDR-TB cases among new pulmonary TB cases notified in 2010 Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010 1.5 (0.802.4) 16 (1319) 140 (72220) 140 (110170) Retreatment 495 57 78 Financing Total budget (US$ millions) 2011 8 2012 9 8 82 87 13 500 0 2003 2004 2005 2006 2007 2008 2009 2010

Total new and relapse Total cases notified

11 420 11 889

(96% of total)

Drug regimens Rifampicin used throughout treatment % of patients treated with fixed-dose combinations (FDCs) Paediatric formulations procured Treatment success rate 2009 (%) New smear-positive New smear-negative/extrapulmonary Retreatment Treatment success rate (%) 80 40 0
19 1995 1996 1997 1998 2099 2000 2001 2002 2003 2004 2005 2006 2007 2008 09

77 71

New smear + New smear-/extrap Retreatment

MDR-TB reported cases 2010 Cases tested for MDR-TB % of notified tested for MDR-TB Confirmed cases of MDR-TB MDR-TB patients started treatment Laboratories Smear (per 100 000 population) Culture (per 5 million population) DST (per 10 million population) Second-line DST available National Reference Laboratory

New 1 240 11 48

Total 2 001 17 131 152 2011 7.8 133.8 0.9

Available funding (US$ millions) 6 % of budget funded 76 % available funding from domestic sources 100 % available funding from Global Fund 0 NTP Budget (blue) and available funding (green) (US$ millions) 12 10 8 6 4 2 2006 2007 2008 2009 2010 2011

2009 5.3 140.8 0.4

2010 7.9 135.7 0.8

In and outside country Yes

2012

* Ranges represent uncertainty intervals

Generated: March 10, 2012

Source: www.who.int/tb/data